Research programme: monoclonal antibody-based therapeutics and diagnostics - multimmune

Drug Profile

Research programme: monoclonal antibody-based therapeutics and diagnostics - multimmune

Alternative Names: mi-TUMEXdx; mi-TUMEXim; mi-TUMEXtx

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator multimmune
  • Class Diagnostic agents; Imaging agents; Monoclonal antibodies
  • Mechanism of Action Diagnostic imaging enhancers; HSP70 heat-shock protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Colorectal cancer; Solid tumours

Most Recent Events

  • 28 Jan 2016 Preclinical trials in Colorectal cancer in Germany (Parenteral)
  • 28 Jan 2016 Preclinical trials in Solid tumours (Diagnosis) in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top